



DEPARTMENT OF HEALTH & HUMAN SERVICES

---

Food and Drug Administration  
Rockville, MD 20857

ANDA 77-480

SICOR Pharmaceuticals, Inc.  
Attention: Sonia Hernandez  
Associate Director, Regulatory Affairs  
19 Hughes  
Irvine, CA 92618-1902

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated December 21, 2004, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Ondansetron and Dextrose Injection, 0.64 mg/mL, packaged in 32 mg/50 mL, single-dose flexible plastic containers.

Reference is also made to the tentative approval letter issued by this office on August 30, 2006, and your amendments dated September 6, November 7, November 15, November 16, and November 17, 2006.

We also acknowledge that on August 29, 2006, GlaxoSmithKline granted TEVA Pharmaceuticals USA (of which SICOR Pharmaceuticals, Inc. is a subsidiary) a selective waiver of the unexpired pediatric exclusivity covering Zofran Injection. This waiver has an effective date of November 22, 2006, which occurs prior to the expiration of GSK's pediatric exclusivity on December 24, 2006.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Ondansetron and Dextrose Injection, 0.64 mg/mL, packaged in 32 mg/50 mL, single-dose flexible plastic containers, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Zofran Injection Premixed in Dextrose, packaged in 32 mg/50 mL, single-dose flexible plastic containers of GlaxoSmithKline.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

*{See appended electronic signature page}*

Gary Buehler  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Robert L. West  
11/22/2006 01:06:57 PM  
for Gary Buehler